Anne Wojcicki, co-founder and CEO of genetic-testing startup 23andMe, discusses the new deals with Pfizer and Genentech.
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.
CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.
CNBC's Meg Tirrell, and Michael Pellini, Foundation Medicine president & CEO, discuss the benefits of Roche's majority stake in Foundation Medicine.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
History says the best play is to buy biotech stocks the day before the JPMorgan meeting starts and hold until the end.
CNBC biotech and pharma reporter Meg Tirrell looks at what to expect from the biggest and most important health care conference of the year. The 33rd annual J.P. Morgan Health Care Conference starts Monday, with 450 companies presenting to almost 9,000 attendees.
Biotech investor Brad Loncar is on a mission to persuade every presenting company at an upcoming biotech conference to also webcast its breakout session.
CNBC's Meg Tirrell provides insight to the debate over transparency from biotech companies. Biotech investor Brad Loncar, thinks this is just an awareness issue.
In an era of rapid technological advances and demographic change, how do legacy companies adapt, innovate and evolve? CNBC Evolve features iconic global companies and executives who are embracing change and transforming for the future.
Cutting across various industries and the public sector, CNBC's Technology Executive Council offers insight on pressing issues facing tech.
Financial advisors stress that now is the time for investors to get serious about year-end financial planning checkup.